Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This 1969 editorial discusses the pathophysiology of circulatory shock and the potential role of isoproterenol in its management.
Editorials1 March 1969Isoproterenol for the Treatment of Circulatory ShockMAX HARRY WEIL, M.D., PH.D., F.A.C.P., HERBERT SHUBIN, M.D., F.A.C.P.MAX HARRY WEIL, M.D., PH.D., F.A.C.P.Search for more papers by this author, HERBERT SHUBIN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-70-3-638 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptLimitation in cardiac competence as a determinant of survival after the onset of circulatory shock has been the subject of important experimental and clinical studies in recent years (1-3). A fundamental although not exclusive defect in shock due to various causes is a significant reduction in cardiac output. Yet when shock occurs in patients who have hepatic cirrhosis or generalized peritonitis, large arteriovenous shunts often account for normal or even increased cardiac output values (4, 5). The portion of the cardiac output that bypasses the capillary exchange circuit does not serve metabolic needs. If the portion available for tissue perfusion...References1. CROWELLGUYTON JWAC: Further evidence favoring cardiac mechanism in irreversible hemorrhagic shock. Amer. J. Physiol. 203: 248, 1962. CrossrefMedlineGoogle Scholar2. ROTHESELKURT CFEE: Cardiac and peripheral failure in hemorrhagic shock in the dog. Amer. J. Physiol. 207: 203, 1964. CrossrefMedlineGoogle Scholar3. CAREYBROWNMOHRMONSONYAOSHOEMAKER JSRSPADOSTWC: Cardiovascular function in shock: responses to volume loading and isoproterenol infusion. Circulation 35: 327, 1967. CrossrefMedlineGoogle Scholar4. UDHOJIWEIL VNMH: Hemodynamic and metabolic studies on shock associated with bacteremia: observations on sixteen patients. Ann. Intern. Med. 62: 966, 1965. LinkGoogle Scholar5. ROSOFFWEILBRADLEYBERNE LMHECCJ: Hemodynamic and metabolic changes associated with bacterial peritonitis. Amer. J. Surg. 114: 180, 1967. CrossrefMedlineGoogle Scholar6. MCLEANDUFFSCOTTPERETZ LDJHHMDI: Treatment of shock in man based on hemodynamic diagnosis. Surg. Gynec. Obstet. 120: 1, 1965. MedlineGoogle Scholar7. SMITHORIOLMORCHMCGREGOR HJAJM: Hemodynamic studies in cardiogenic shock: treatment with isoproterenol and metaraminol. Circulation 35: 1084, 1967. CrossrefMedlineGoogle Scholar8. FEARON RE: Comparison of norepinephrine and isoproterenol in experimental coronary shock. Amer. Heart J. 634, 1968. CrossrefMedlineGoogle Scholar9. STARZECKIREDDINSPINK BJLWW: Effect of isoproterenol on survival in canine endotoxin shock. Ann. Surg. 167: 35, 1968. CrossrefMedlineGoogle Scholar10. LEWISWEIL CMMH: Hemodynamic spectrum of vasopressor and vasodilator drugs. JAMA. In press. Google Scholar11. GREGAKINNARDBUCKLEY GJWJJP: Effects of nylidrin, isoproterenol and phenoxybenzamine on dogs subjected to hemorrhagic shock. Circ. Res. 20: 253, 1967. CrossrefMedlineGoogle Scholar12. STARZECKISPINK BW: Hemodynamic effects of isoproterenol in canine endotoxin shock. J. Clin. Invest. 47: 2193, 1968. CrossrefMedlineGoogle Scholar13. WEILWHIGHAMBRADLEY MHHEC: Isoproterenol for treatment of experimental shock produced by hemorrhage (abstract). Circulation 34 (suppl. III): 236, 1966. Google Scholar14. HERSHEYALTURAORKIN SGBMLR: Therapy of intestinal ischemic (SMA) shock with vasoactive drugs. Anesthesiology 29: 466, 1968. CrossrefMedlineGoogle Scholar15. GRUNINGERSPINK RPWW: Protection against lethality of endotoxin with isoproterenol: the chick embryo as an experimental model. Proc. Soc. Exp. Biol. Med. 124: 1277, 1967. CrossrefMedlineGoogle Scholar16. DU PLESSISDU TOITBULLRORKE JMHJABMJ: The role of isoproterenol in the therapy of shock. S. Afr. Med. J. 41: 524, 1967. MedlineGoogle Scholar17. GUNNARLOCHPIETRASTOBIN RMHSRJJR: Ineffectiveness of isoproterenol in shock due to acute myocardial infarction. JAMA 202: 1124, 1967. CrossrefMedlineGoogle Scholar18. WEILBRADLEYSHUBIN MHECH: Unpublished observations. Google Scholar19. COHENELLIOTKLEINGORLIN LSWCMDR: Coronary heart disease: clinical, cinearteriographic and metabolic correlations. Amer. J. Cardiol. 17: 153, 1966. CrossrefMedlineGoogle Scholar20. KENNEDYBAILAS JHN: Support of the failing circulation: effects of isoproterenol in experimental left ventricular failure. Cardiologia 50: 108, 1967. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Southern California School of Medicine Los Angeles, Calif. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByEfficient and selective analytical method for the quantification of a β -adrenoceptor agonist, isoproterenol, by LC–MS/MS and its application to pharmacokinetics studiesContrasting effects of dopamine and isoproterenol in experimental myocardial infarctionAcute renal failure in obstetric septic shockSeptic ShockIsoproterenol and norepinephrine therapy for pulmonary embolism shockPathophysiology of gram-negative shockInfluence of adrenergic ?-receptor activity on blood flow and free fatty acid release in canine subcutaneous adipose tissue during hemorrhagic shockTreatment of gram-negative shockPractical considerations in the management of shock complicating acute myocardial infarctionPathophysiology and Therapy of the Shock of Myocardial InfarctionFRANCIS J. HADDY, M.D., Ph.D., F.A.C.P. 1 March 1969Volume 70, Issue 3Page: 638-641KeywordsCapillariesCardiac outputCirrhosisIsoproterenolPeritonitisShock Issue Published: 1 March 1969 PDF DownloadLoading ...
No takes yet. Share an insight, caveat, or question.
Max Harry Weil (1969) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: